侵袭性乳腺癌保留乳头乳晕复合体乳房切除术后乳头乳晕复合体复发研究
该回顾性队列研究纳入944例侵袭性乳腺癌患者(962侧乳房),接受保留乳头乳晕复合体乳房切除术(NSM)和即刻乳房重建,中位随访85个月,首次事件为乳头乳晕复合体(NAC)复发者39例(4.1%),5年累积发生率3.5%。多因素分析显示多灶/多中心、激素受体阴性/ERBB2阳性亚型、高组织学分级和广泛导管内成分是NAC复发的独立危险因素。NAC复发与无远处转移生存和总生存无显著差异。
要点
- NSM术后NAC复发率低,5年累积发生率3.5%。
- 多灶/多中心、HR阴性/ERBB2阳性、高分级、广泛导管内成分增加NAC复发风险。
- NAC复发未显著影响无远处转移生存和总生存。
核心结论
- NSM联合即刻乳房重建后NAC复发率低。
- 多灶/多中心、激素受体阴性/ERBB2阳性亚型、高组织学分级和广泛导管内成分应在决定NSM前予以考虑。
研究设计与样本
- 排除接受新辅助全身治疗或姑息性手术的患者。
主要发现
- 中位随访85个月,39例(4.1%)以NAC复发为首发事件,5年累积发生率为3.5%(n=34)。
- 多因素分析显示多灶/多中心(HR 3.309;95%CI 1.501-7.294;P=.003)、激素受体阴性/ERBB2阳性亚型(HR 3.051;95%CI 1.194-7.796;P=.02)、高组织学分级(HR 2.641;95%CI 1.132-6.160;P=.03)和广泛导管内成分(HR 3.338;95%CI 1.262-8.824;P=.02)与NAC复发独立相关。
- 39例复发患者均接受广泛局部切除术。
- NAC复发组与无复发组在无远处转移生存(P=.95)和总生存(P=.21)上无显著差异。
- NAC复发组与无复发组的10年无远处转移生存率分别为89.3%和94.3%,10年总生存率分别为100%和94.5%。
临床怎么用
- 对于具有多灶/多中心、激素受体阴性/ERBB2阳性亚型、高组织学分级或广泛导管内成分的侵袭性乳腺癌患者,在决定NSM前应综合评估NAC复发风险。
- NSM术后NAC复发患者可采用广泛局部切除术治疗。
局限性
- 单中心回顾性研究。
- 中位随访85个月,长期随访数据仍有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The main concern associated with nipple-sparing mastectomy (NSM) is the risk of local breast cancer recurrence at the retained nipple-areola complex (NAC) consequent to occult nipple involvement. Long-term follow-up data regarding the oncologic safety of modern therapeutic NSM in terms of cancer recurrence at the NAC and survival are limited. OBJECTIVE: To assess the incidence, risk factors, treatment, and long-term outcomes associated with cancer recurrence at the NAC in a large series of patients with invasive breast cancer who underwent NSM and immediate breast reconstruction. DESIGN, SETTING, AND PARTICIPANTS: In this retrospective cohort study at a single institution (Asan Medical Center) in Seoul, Republic of Korea, 962 breasts from 944 patients who underwent NSM and immediate breast reconstruction for invasive breast cancer were analyzed between March 3, 2003, and December 31, 2015. Patients who underwent neoadjuvant systemic therapy or palliative surgery were excluded. Data analysis was performed from June 4, 2018, to August 31, 2018. MAIN OUTCOMES AND MEASURES: Univariate and multivariate Cox proportional hazards regression models were used to analyze the association between clinicopathologic variables and cancer recurrence at the NAC. To evaluate the association between cancer recurrence at the NAC and prognosis, distant metastasis-free survival, and overall survival were estimated using the Kaplan-Meier method and compared using the log-rank test. RESULTS: Among the 944 study patients (median age at diagnosis, 43 years [range, 23-67 years]) during a median follow-up of 85 months (range, 14-185 months), 39 cases (4.1%) of cancer recurrence at the NAC were identified as the first event after NSM. The 5-year cumulative incidence of cancer recurrence at the NAC was 3.5% (n = 34). In multivariate analyses, multifocality or multicentricity (hazard ratio [HR], 3.309; 95% CI, 1.501-7.294; P = .003), negative hormone receptor or ERBB2 (formerly HER2 or HER2/neu)-positive subtype (HR, 3.051; 95% CI, 1.194-7.796; P = .02), high histologic grade (HR, 2.641; 95% CI, 1.132-6.160; P = .03), and extensive intraductal component (HR, 3.338; 95% CI, 1.262-8.824; P = .02) were independently associated with cancer recurrence at the NAC after NSM. All 39 recurrent cases involved wide local excision. Patients with and without cancer recurrence at the NAC as the first event did not differ significantly with regard to distant metastasis-free survival (P = .95) or overall survival (P = .21). The 10-year distant metastasis-free survival rates were 89.3% among patients with cancer recurrence at the NAC and 94.3% among patients without recurrence. The 10-year overall survival rates were 100% among patients with cancer recurrence at the NAC and 94.5% among those without recurrence. CONCLUSIONS AND RELEVANCE: Patients had a low incidence of cancer recurrence at the NAC after NSM and immediate breast reconstruction in this study. The findings suggest that multifocal or multicentric disease, hormone receptor-negative/ERBB2-positive subtype, high histologic grade, and positive extensive intraductal component should be considered before determining the NSM procedure.
引用
- Wu ZY, Kim HJ, Lee JW, et al. Breast Cancer Recurrence in the Nipple-Areola Complex After Nipple-Sparing Mastectomy With Immediate Breast Reconstruction for Invasive Breast Cancer. JAMA Surg. 2019. PMID: 31461141. doi:10.1001/jamasurg.2019.2959
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。